Trials / Terminated
TerminatedNCT05838755
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 147 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK3858279 | GSK3858279 was administered |
| DRUG | Placebo | Placebo was administered |
Timeline
- Start date
- 2023-09-20
- Primary completion
- 2024-10-14
- Completion
- 2025-02-17
- First posted
- 2023-05-03
- Last updated
- 2025-11-21
- Results posted
- 2025-11-21
Locations
81 sites across 11 countries: United States, Canada, China, France, Germany, Japan, Poland, South Africa, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05838755. Inclusion in this directory is not an endorsement.